Livalo Overview
First approved by the U.S. Food & Drug Administration (FDA) in August 2009, Livalo is a widely-prescribed HMG-CoA reductase inhibitor or “statin” drug. Statins like Livalo are designed to lower cholesterol by reducing the activity of an enzyme in the liver that is necessary for the production of cholesterol. Lowering cholesterol levels may help prevent heart disease and hardening of the arteries, conditions that can lead to heart attacks, strokes, and vascular disease.
